Psoriasis is a chronic inflammatory skin disease. This study investigated the effects of sulforaphane (SFN) on a mouse model of psoriasis and its molecular mechanism. SFN treatment improved psoriatic symptoms, reduced inflammation markers, and activated the KEAP1-NRF2 pathway. NRF2-deficient mice showed aggravated psoriasis, suggesting SFN's therapeutic potential via the KEAP1-NRF2 pathway.